FIGHT Study in Gastric/Gastroesophageal Junction Cancer
During this interview with Prof Dr Zev Wainberg from the University of California, Los Angeles, he presents the final analysis of the FIGHT Trial. This significant study investigated the efficacy of bemarituzumab, a monoclonal antibody that selectively inhibits FGFR2b signalling and enhances antibody-dependent cellular toxicity against tumour cells expressing FGFR2b. The trial evaluated the addition of bemarituzumab to the standard treatment of mFOLFOX6 as a first-line therapy for locally advanced or metastatic gastric/gastroesophageal junction cancer.
With the educational support of:
